BRNS (Barinthus Biotherapeutics) LT-Debt-to-Total-Asset : 0.06 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Barinthus Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.06.

Barinthus Biotherapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.05) to Dec. 2024 (0.06). It may suggest that Barinthus Biotherapeutics is progressively becoming more dependent on debt to grow their business.

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Barinthus Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.91

0.02

0.03

0.05

0.06

Barinthus Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.06	0.06	0.06	0.06

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Calculation

Barinthus Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	10.087	/	160.327
	=	0.06

Barinthus Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	10.087	/	160.327
	=

Barinthus Biotherapeutics (NAS:BRNS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Barinthus Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Barinthus Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF

Website

https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Executives

Joseph Scheeren	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright	director, officer: Chief Executive Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier	officer: Chief Scientific Officer	C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown	officer: Chief Financial Officer	VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths	officer: Chief Business Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis	officer: Chief Operating Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall	officer: Chief Medical Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans	officer: Chief Scientific Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov	officer: Chief Financial Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE